Pharmaceuticals

Phesgo Market Forecast 2026–2035: Data Trends and Industry Insights

March 6, 2026March 8, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the phesgo market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Phesgo Market in 2026, and what figure is it projected to hit by 2030?

The growth observed in the historical period was primarily driven by a rise in the diagnosis of HER2-positive breast cancer, alongside advancements in the development of monoclonal antibodies, the expansion of oncology infusion centers, improved patient survival outcomes attributed to targeted therapy, and an increase in the approvals of biologic drugs.

The anticipated expansion during the forecast period is propelled by several factors, including the increasing availability of oncology treatment models accessible from home, a surge in investments directed towards combination biologic therapies, the rising embrace of subcutaneous drug delivery methods, significant progress in technologies that enhance formulation stability, and an escalating demand for highly effective cancer treatment protocols.

Significant trends expected in the forecast period feature the accelerating adoption of fixed-dose combination therapies, a heightened preference for subcutaneous oncology treatments, the continuous expansion of therapeutic options for HER2-positive breast cancer, an increasing dedication to improving patient convenience and compliance, and advancements in biologic formulation technologies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20347&type=smp

Which Drivers Are Affecting Market Participation In The Phesgo Market?

The rising prevalence of breast cancer is projected to fuel the expansion of the phesgo market moving forward. Breast cancer is a malignancy originating in breast cells, typically within the milk ducts or lobules, with the potential to spread to other areas of the body. The escalating incidence of breast cancer is linked to elements including aging populations, genetic predispositions, shifts in lifestyle, environmental exposures, and hormonal influences. Phesgo assists breast cancer patients by providing a convenient fixed-dose therapy combining pertuzumab and trastuzumab, two targeted treatments that act together to suppress the HER2 protein, which promotes tumor development, while simultaneously decreasing administration duration and enhancing the overall patient experience. For instance, according to the American Cancer Society, a US-based professional organization, the number of new breast cancer cases in the United States increased from 300,590 in 2023 to 313,510 in 2024. Consequently, the rising occurrence of breast cancer is propelling the phesgo market forward. The increasing need for personalized medicine is anticipated to foster the expansion of the phesgo market going forward. Personalized medicine involves customizing medical interventions according to the specific attributes of each patient, such as genetic profile, daily habits, and surroundings, aiming for more precise and impactful treatments. The growing demand for personalized medicine is stemming from progress in genomic research, which facilitates customized therapies that enhance results and mitigate adverse reactions. Phesgo contributes to personalized medicine through its combination of pertuzumab and trastuzumab, two targeted treatments designed to inhibit the HER2 protein in HER2-positive breast cancer patients, into a single, subcutaneous injection that simplifies treatment administration and meets individual patient requirements for precise healthcare. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Consequently, the increasing demand for personalized medicine is fueling the phesgo market’s growth.

What Segment Categories Are Covered In The Phesgo Market?

The phesgo market covered in this report is segmented –

1) By Indication: Early Breast Cancer, Metastatic Breast Cancer

2) By Formulation: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors

4) By End User: Hospitals, Oncology Clinics, Home Healthcare

What Trends Are Projected To Support The Growth Of The Phesgo Market?

Leading firms within the phesgo market are concentrating on bringing forth novel treatments like monoclonal antibody combination therapy, aiming to boost treatment effectiveness and better patient results in cancer care. Monoclonal antibody combination therapy involves administering two or more distinct monoclonal antibodies concurrently to address various facets of an illness, frequently leading to enhanced treatment efficacy and the circumvention of possible resistance pathways. An example is the launch of Phesgo combination for Subcutaneous Injection MA, IN in November 2023 by Chugai Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan. This medication, Phesgo, is an injectable blend that delivers pertuzumab and trastuzumab, which are both monoclonal antibodies, alongside hyaluronidase alfa, designed to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, providing an easy subcutaneous delivery option instead of intravenous infusion.

Which Leading Companies Dominate The Phesgo Market Share?

Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/phesgo-global-market-report

How Does The Phesgo Market Perform Across Major Global Regions?

North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phesgo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Phesgo Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20347&type=smp

Browse Through More Reports Similar to the Global Phesgo Market 2026, By The Business Research Company

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Phosphoric Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosphoric-acid-global-market-report

Automated Algo Trading Market Report 2026

https://www.thebusinessresearchcompany.com/report/automated-algo-trading-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795